Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.
Redwood City, United States of AmericaPharmaceuticals & Biotech
Merck Group, also known as Merck KGaA, is a prominent global science and technology company based in Darmstadt, Germany. Founded in 1668, it is recognized as the world's oldest pharmaceutical and chemical company. Merck Group operates in three main sectors: healthcare, life sciences, and electronics, employing around 50,000 people worldwide.
In the healthcare sector, Merck develops pharmaceuticals, including therapies for oncology, neurology, and immunology. The life sciences division offers tools and technologies for research and bioprocessing, featuring MilliporeSigma for lab products. The electronics segment supplies materials for semiconductors and display technologies. Additionally, Merck provides research and development services, custom chemical manufacturing, and consulting support in drug discovery and materials science. The company emphasizes values such as responsibility, integrity, and transparency, maintaining a strong commitment to innovation throughout its long history.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, includingmore
Thousand Oaks, United States of AmericaPharmaceuticals & Biotech
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Coriolis Pharma is a globally operating contract research and development organization specializing in the formulation research and development of biopharmaceutical drugs, including cell and gene therapy products and vaccines.